Compensation for cures: Why we should pay a premium for participation in 'challenge studies'
Compensation for cures: Why we should pay a premium for participation in 'challenge studies'
复制标题
DOI：
10.1111/bioe.12596
复制
发表时间：
2019-09-01
期刊：
影响因子：
2.2
通讯作者：
Savulescu, Julian
中科院分区：
文献类型：
--
作者：
Anomaly, Jonathan;Savulescu, Julian
抗生素耐药性是人类面临的最紧迫的公共卫生问题之一。研究新的抗生素和新的治疗方法--包括噬菌体疗法和疫苗等危险的实验性治疗方法--是提高我们治疗传染病能力的重要组成部分。为了帮助这项研究，我们将主张，我们应该允许研究人员向人们支付任何金额的钱，以补偿参与临床试验的风险，包括涉及故意感染患者的“挑战性研究”。我们认为，对于为参与风险研究付费的标准担忧可以简化为可以通过正确的筛选机制解决的担忧。
Antibiotic resistance is one of the most pressing public health problems humanity faces. Research into new classes of antibiotics and new kinds of treatments - including risky experimental treatments such as phage therapy and vaccines - is an important part of improving our ability to treat infectious diseases. In order to aid this research, we will argue that we should permit researchers to pay people any amount of money to compensate for the risks of participating in clinical trials, including 'challenge studies' that involve deliberately infecting patients. We think that standard worries about paying for participation in risky research are reducible to concerns that can be addressed with the right screening mechanisms.